SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SX-682’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SX-682 overview
SX-682 is under development for the treatment of myelodysplastic syndrome, metastatic pancreatic ductal adenocarcinoma, solid tumor, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), triple-negative breast cancer (TNBC), head and neck cancer squamous cell carcinoma, oropharyngeal cancer, metastatic melanoma and colorectal cancer and non-small cell lung cancer. It is administered orally. The drug candidate is an allosteric inhibitor of CXCR1/2 chemokine receptors on the surface of neutrophil cell membranes. It was also under development for chronic obstructive pulmonary disease (COPD), severe asthma and bronchopulmonary dysplasia (BPD).
Syntrix Pharmaceuticals overview
Syntrix Pharmaceuticals (Syntrix) is a clinical-stage company primarily engaged in the development of innovative medicines for patients. The company’s main activities involve scientific research, new drug development, and the creation of breakthrough therapies in immuno-oncology and pain management. Syntrix’s major products include SX-682, a potent small-molecule dual-inhibitor for cancer treatment, and Desmetramadol, a pain relief medication. The company’s products are designed to address unmet medical needs and are used in various clinical oncology indications and pain management. It collaborates with university researchers, manufacturers, and clinical trial teams globally. Syntrix is headquartered in Auburn, Washington, the US.
For a complete picture of SX-682’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
